Hua Medicine Announces 2024 Annual Results
Hua Medicine Announces 2024 Annual Results - HuaTangNing completed its first full year for reimbursement under the National Reimbursement D ...
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
Fierce Pharma58m
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Shanghai Pharmaceuticals Holding Is the Second-Largest Medical Distributor in China
We think SPH is in a good financial position. In the past three years, its debt over capital has been stable at around 0.4 times. Despite not being in a net cash position, it has enough cash to ...
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...